Volume 27, Number 6—June 2021
Research
Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA
Mariana M. Lanata1, Huanyu Wang, Kathy Everhart, Melisa Moore-Clingenpeel, Octavio Ramilo, and Amy Leber
Table 8
Antimicrobial drug treatment for children infected with Mycoplasma pneumoniae, Ohio, USA, 2015–2019*
| Characteristic | MRMp, n = 12 | MSMp, n = 332 | p value |
|---|---|---|---|
| Patients with previous antimicrobial drug treatment, no. (%) | 5 (42) | 106 (32) | 0.5339 |
| Nonmacrolide | 5 (42) | 102 (31) | 0.5262 |
| Macrolide |
3 (25) |
7 (2.1) |
0.0017 |
| Definitive treatment during medical encounter, no. (%) | |||
| Azithromycin | 9 (75) | 317 (95.5) | 0.0197 |
| Levofloxacin | 3 (25) | 15 (4.5) | 0.0267 |
*Bold type indicates statistical significance. MRMp, macrolide-resistant Mycoplasma pneumoniae; MSMp, macrolide-sensitive Mycoplasma pneumoniae.
1Current affiliation: Marshall University, Huntington, West Virginia, USA.
Page created: March 30, 2021
Page updated: May 18, 2021
Page reviewed: May 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.